icon-    folder.gif   Conference Reports for NATAP  
  IAS 2017: Conference on HIV Pathogenesis
Treatment and Prevention
Paris, France
July 23-26 2017
Back grey_arrow_rt.gif
Peripheral blood and cerebrospinal fluid viremia of 24-weeks MONOtherapy of DOlutegravir in HIV-1 virologically suppressed patients: MONODO study
  Dolutegravir monotherapy: when should clinical practice be clinical research? - Commentary - (02/18/17)
DOMONO study - CROI: Dolutegravir as Maintenance Monotherapy for HIV-1: a Randomized Clinical Trial - (02/23/17)
Dual ARTs: IAS: New HIV & HCV Drugs at IAS / Dual ARTs / Fatty Liver in HIV+ - (08/09/17)
Reported by Jules Levin
9th IAS Conference on HIV Science (IAS 2017), July 23-26, 2017, Paris
Thanh Doco Lecompte1*, Delphine Sculier1*, Sabine Yerly2, Laurent Decosterd3, Olivier Nawej1, Yoana Dimitrova1 and Alexandra Calmy1. * equal contribution 1 HIV unit, 2 Laboratory of Virology, Geneva University Hospital, Switzerland. 3 Clinical pharmacology laboratory, CHUV, Lausanne, Switzerland






1. Rojas J, et al. Dolutegravir Monotherapy in HIV-infected Patients with Sustained Viral Suppression: A 24-week Pilot Study. 15th Conference of the European AIDS Clinical Society. Barcelona, Spain; 2015.
2. Oldenbuettel et al. Dolutegravir monotherapy as treatment de-escalation in HIV-infected adults with virological control: DoluMono cohort results. Antivir Ther 2016.
3. Katlama Cet al. Dolutegravir Monotherapy in HIV-Infected Patients with Suppressed HIV Viremia 15th Conference of the European AIDS Clinical Society. Barcelona, Spain 2015.